Merial, the animal health division of Sanofi, has announced its acquisition of Newport Laboratories, a Worthington, Minn.-based privately held company and manufacturer of autogenous vaccines with a focus on swine and cattle production markets.
Newport Laboratories assists veterinarians and pork producers by addressing animal health problems through diagnostic testing and production of veterinary biologics. Newport Laboratories is the nation’s leading manufacturer of autogenous biologics, as noted on the company’s website.
“Joining forces with Merial allows us to expand our expertise in the market and enhance the profitability of our customers through solution-based animal healthcare offerings,” says Randy Simonson, chief operating officer, Newport Laboratories.
This acquisition will enable Merial to expand its business to address the U.S. production animal sector while providing a unique opportunity to meet the needs of U.S. pork producers. Newport Laboratories will continue to operate from its Worthington site and maintain its high level of service to its customers, officials say.
“The combination of Newport’s expertise and Merial’s strength in technology and geographic footprint will reinforce our exposure to the swine market segment and illustrates our strategy to expand our position in treatments for production animals,” says Jose Barella, Merial’s chief executive officer.